NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Well Positioned to Move next NanoAb Candidates into Clinical Application

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently signed an exclusive worldwide license agreement to develop and commercialize VHH antibodies (“NanoAbs”) that target Interleukin-17 (“IL-17”). “The license agreement is part of a broad-based collaboration with the Max Planck Society and the University Medical Center Göttingen (‘UMG’). The NanoAbs will be targeted toward the treatment of several relevant indications, including, but not limited to, psoriasis and psoriatic arthritis. BiondVax’s collaboration with the Max Planck Institute for Multidisciplinary Sciences and UMG, both based in Germany, is producing a pipeline of innovative therapies addressing diseases underserved by current treatments, yet with large and growing markets,” a recent article reads. “According to Dr. Dieter Link, patent and licensing manager at Max Planck Innovation, this milestone marks a significant step toward the clinical application of the next VHH antibody candidates out of the larger group of NanoAbs contemplated by the collaborators. ‘BiondVax is well positioned to move this closer to and into clinical application,’ he said.” To view the full article, visit https://nnw.fm/3WGN5 About BiondVax Pharmaceuticals Ltd. BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, BiondVax has executed eight clinical trials including a seven-country, 12,400-participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com. NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://nnw.fm/BVXV About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only) For more information please visit https://www.networknewswire.com Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer NetworkNewsWire (NNW) New York, New York www.networknewswire.com 212.418.1217 Office Editor@NetworkNewsWire.com NetworkNewsWire is part of the InvestorBrandNetwork.